Loading…
Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis
In the present systematic review and meta-analysis, we sought to compare the efficacy and safety of tirofiban administered in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT). We searched PubMed, Web of Science, Embase and th...
Saved in:
Published in: | Clinical neurology and neurosurgery 2022-11, Vol.222, p.107449, Article 107449 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83 |
---|---|
cites | cdi_FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83 |
container_end_page | |
container_issue | |
container_start_page | 107449 |
container_title | Clinical neurology and neurosurgery |
container_volume | 222 |
creator | Liu, Qianqian Lu, Xianfu Yang, Hong Deng, Shan Zhang, Jian Chen, Shijian Shi, Shengliang Xun, Weiquan Peng, Rihong Lin, Baoquan Li, Tao Pan, Liya Weng, Baohui |
description | In the present systematic review and meta-analysis, we sought to compare the efficacy and safety of tirofiban administered in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT).
We searched PubMed, Web of Science, Embase and the Cochrane Library for randomized clinical trials and observational studies published between 2001 and 2021 that provided outcomes of AIS patients who underwent IVT alone or IVT bridging with or without tirofiban. The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–2 at 90 days. The secondary outcomes included the rates of (1) an excellent outcome defined as a mRS score of 0 or 1 at 90 days, (2) any type of intracranial hemorrhage (ICH), (3) symptomatic intracranial hemorrhage (sICH), (4) mortality, and (5) successful recanalization.
We included 722 patients with IVT bridging therapy in 3 trials; there were 171 patients in the tirofiban group and 551 patients in the nontirofiban group. We included 846 patients with IVT alone in 7 studies; there were 471 patients in the tirofiban group and 375 patients in the nontirofiban group. The patients treated with tirofiban had a reduced risk of mortality compared to the patients treated without tirofiban during IVT bridging (OR, 0.46; 95 % CI, 0.24–0.89; p = 0.02), but no significant differences were found in safety outcomes on sICH, ICH, recanalization or efficacy outcomes on modified Rankin scale 0–2 (p > 0.05). Pooled results showed that tirofiban combined with IVT alone did not increase the risks of sICH, ICH or mortality but was significantly associated with excellent (OR, 2.68; 95 % CI, 1.58–4.55; P = 0.0003) and favorable (OR, 2.36; 95 % CI, 1.58–3.52; p |
doi_str_mv | 10.1016/j.clineuro.2022.107449 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2727397425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846722003304</els_id><sourcerecordid>2727397425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EEkvhFZAlzllsJ3ESTqCqBaRKHICzNXYmXS8bexk7rfJAvCdeAmdOHnm-_7dnfsZeS7GXQuq3x707-YALxb0SSpXLrmmGJ2wn-05VetD9U7YTtairvtHdc_YipaMQoq51v2O_boBOK8-e4uQtBA7j7INPmSD7GPgUiZ9LiSEn_ujzgYNbMnKf3AFn73gh4w_kmRAyjhviQ5E_YIhL4vlAcbbxtCafeDGz5Md7H-5LAwnO6zv-dU0Z5_KG44QPHh85hJHPmKGCAH-EL9mzCU4JX_09r9j325tv15-quy8fP19_uKtco2Su3Ng7KW3dOgt2nFqrwcrB4eCELPVQw6Cl7tpOCnGh0AnRtD0oNWhrp76-Ym823zPFnwumbI5xofKJZFSnunroGtUWSm-Uo5gS4WTO5Geg1UhhLpGYo_kXiblEYrZIivD9JsQyQ5mUTHJlsw5HT-iyGaP_n8VvN2CeZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2727397425</pqid></control><display><type>article</type><title>Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis</title><source>Elsevier</source><creator>Liu, Qianqian ; Lu, Xianfu ; Yang, Hong ; Deng, Shan ; Zhang, Jian ; Chen, Shijian ; Shi, Shengliang ; Xun, Weiquan ; Peng, Rihong ; Lin, Baoquan ; Li, Tao ; Pan, Liya ; Weng, Baohui</creator><creatorcontrib>Liu, Qianqian ; Lu, Xianfu ; Yang, Hong ; Deng, Shan ; Zhang, Jian ; Chen, Shijian ; Shi, Shengliang ; Xun, Weiquan ; Peng, Rihong ; Lin, Baoquan ; Li, Tao ; Pan, Liya ; Weng, Baohui</creatorcontrib><description>In the present systematic review and meta-analysis, we sought to compare the efficacy and safety of tirofiban administered in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT).
We searched PubMed, Web of Science, Embase and the Cochrane Library for randomized clinical trials and observational studies published between 2001 and 2021 that provided outcomes of AIS patients who underwent IVT alone or IVT bridging with or without tirofiban. The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–2 at 90 days. The secondary outcomes included the rates of (1) an excellent outcome defined as a mRS score of 0 or 1 at 90 days, (2) any type of intracranial hemorrhage (ICH), (3) symptomatic intracranial hemorrhage (sICH), (4) mortality, and (5) successful recanalization.
We included 722 patients with IVT bridging therapy in 3 trials; there were 171 patients in the tirofiban group and 551 patients in the nontirofiban group. We included 846 patients with IVT alone in 7 studies; there were 471 patients in the tirofiban group and 375 patients in the nontirofiban group. The patients treated with tirofiban had a reduced risk of mortality compared to the patients treated without tirofiban during IVT bridging (OR, 0.46; 95 % CI, 0.24–0.89; p = 0.02), but no significant differences were found in safety outcomes on sICH, ICH, recanalization or efficacy outcomes on modified Rankin scale 0–2 (p > 0.05). Pooled results showed that tirofiban combined with IVT alone did not increase the risks of sICH, ICH or mortality but was significantly associated with excellent (OR, 2.68; 95 % CI, 1.58–4.55; P = 0.0003) and favorable (OR, 2.36; 95 % CI, 1.58–3.52; p < 0.0001) functional outcomes at 90 days.
In AIS patients who underwent IVT or bridging therapy, early administration of tirofiban may be effective and safe, but further studies are needed to confirm the efficacy.
•To evaluate the safety and efficacy of tirofiban therapy in patients with AIS after IVT.•Tirofiban could improve the 3-month functional outcome of AIS patients.•Tirofiban after IVT did not increase the risk of sICH or ICH.•Tirofiban reduced the mortality of AIS patients when administered in IVT bridging therapy.</description><identifier>ISSN: 0303-8467</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2022.107449</identifier><language>eng</language><publisher>Assen: Elsevier B.V</publisher><subject>Acute ischemic stroke ; Bridging therapy ; Citation management software ; Clinical trials ; Collaboration ; FDA approval ; Glycoproteins ; Hemorrhage ; Intravenous administration ; Intravenous thrombolysis ; Ischemia ; Meta-analysis ; Mortality ; Observational studies ; Patients ; Risk assessment ; Stroke ; Systematic review ; Thrombolysis ; Tirofiban</subject><ispartof>Clinical neurology and neurosurgery, 2022-11, Vol.222, p.107449, Article 107449</ispartof><rights>2022 The Authors</rights><rights>2022. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83</citedby><cites>FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Liu, Qianqian</creatorcontrib><creatorcontrib>Lu, Xianfu</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><creatorcontrib>Deng, Shan</creatorcontrib><creatorcontrib>Zhang, Jian</creatorcontrib><creatorcontrib>Chen, Shijian</creatorcontrib><creatorcontrib>Shi, Shengliang</creatorcontrib><creatorcontrib>Xun, Weiquan</creatorcontrib><creatorcontrib>Peng, Rihong</creatorcontrib><creatorcontrib>Lin, Baoquan</creatorcontrib><creatorcontrib>Li, Tao</creatorcontrib><creatorcontrib>Pan, Liya</creatorcontrib><creatorcontrib>Weng, Baohui</creatorcontrib><title>Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis</title><title>Clinical neurology and neurosurgery</title><description>In the present systematic review and meta-analysis, we sought to compare the efficacy and safety of tirofiban administered in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT).
We searched PubMed, Web of Science, Embase and the Cochrane Library for randomized clinical trials and observational studies published between 2001 and 2021 that provided outcomes of AIS patients who underwent IVT alone or IVT bridging with or without tirofiban. The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–2 at 90 days. The secondary outcomes included the rates of (1) an excellent outcome defined as a mRS score of 0 or 1 at 90 days, (2) any type of intracranial hemorrhage (ICH), (3) symptomatic intracranial hemorrhage (sICH), (4) mortality, and (5) successful recanalization.
We included 722 patients with IVT bridging therapy in 3 trials; there were 171 patients in the tirofiban group and 551 patients in the nontirofiban group. We included 846 patients with IVT alone in 7 studies; there were 471 patients in the tirofiban group and 375 patients in the nontirofiban group. The patients treated with tirofiban had a reduced risk of mortality compared to the patients treated without tirofiban during IVT bridging (OR, 0.46; 95 % CI, 0.24–0.89; p = 0.02), but no significant differences were found in safety outcomes on sICH, ICH, recanalization or efficacy outcomes on modified Rankin scale 0–2 (p > 0.05). Pooled results showed that tirofiban combined with IVT alone did not increase the risks of sICH, ICH or mortality but was significantly associated with excellent (OR, 2.68; 95 % CI, 1.58–4.55; P = 0.0003) and favorable (OR, 2.36; 95 % CI, 1.58–3.52; p < 0.0001) functional outcomes at 90 days.
In AIS patients who underwent IVT or bridging therapy, early administration of tirofiban may be effective and safe, but further studies are needed to confirm the efficacy.
•To evaluate the safety and efficacy of tirofiban therapy in patients with AIS after IVT.•Tirofiban could improve the 3-month functional outcome of AIS patients.•Tirofiban after IVT did not increase the risk of sICH or ICH.•Tirofiban reduced the mortality of AIS patients when administered in IVT bridging therapy.</description><subject>Acute ischemic stroke</subject><subject>Bridging therapy</subject><subject>Citation management software</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>FDA approval</subject><subject>Glycoproteins</subject><subject>Hemorrhage</subject><subject>Intravenous administration</subject><subject>Intravenous thrombolysis</subject><subject>Ischemia</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Patients</subject><subject>Risk assessment</subject><subject>Stroke</subject><subject>Systematic review</subject><subject>Thrombolysis</subject><subject>Tirofiban</subject><issn>0303-8467</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi0EEkvhFZAlzllsJ3ESTqCqBaRKHICzNXYmXS8bexk7rfJAvCdeAmdOHnm-_7dnfsZeS7GXQuq3x707-YALxb0SSpXLrmmGJ2wn-05VetD9U7YTtairvtHdc_YipaMQoq51v2O_boBOK8-e4uQtBA7j7INPmSD7GPgUiZ9LiSEn_ujzgYNbMnKf3AFn73gh4w_kmRAyjhviQ5E_YIhL4vlAcbbxtCafeDGz5Md7H-5LAwnO6zv-dU0Z5_KG44QPHh85hJHPmKGCAH-EL9mzCU4JX_09r9j325tv15-quy8fP19_uKtco2Su3Ng7KW3dOgt2nFqrwcrB4eCELPVQw6Cl7tpOCnGh0AnRtD0oNWhrp76-Ym823zPFnwumbI5xofKJZFSnunroGtUWSm-Uo5gS4WTO5Geg1UhhLpGYo_kXiblEYrZIivD9JsQyQ5mUTHJlsw5HT-iyGaP_n8VvN2CeZQ</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Liu, Qianqian</creator><creator>Lu, Xianfu</creator><creator>Yang, Hong</creator><creator>Deng, Shan</creator><creator>Zhang, Jian</creator><creator>Chen, Shijian</creator><creator>Shi, Shengliang</creator><creator>Xun, Weiquan</creator><creator>Peng, Rihong</creator><creator>Lin, Baoquan</creator><creator>Li, Tao</creator><creator>Pan, Liya</creator><creator>Weng, Baohui</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>202211</creationdate><title>Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis</title><author>Liu, Qianqian ; Lu, Xianfu ; Yang, Hong ; Deng, Shan ; Zhang, Jian ; Chen, Shijian ; Shi, Shengliang ; Xun, Weiquan ; Peng, Rihong ; Lin, Baoquan ; Li, Tao ; Pan, Liya ; Weng, Baohui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute ischemic stroke</topic><topic>Bridging therapy</topic><topic>Citation management software</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>FDA approval</topic><topic>Glycoproteins</topic><topic>Hemorrhage</topic><topic>Intravenous administration</topic><topic>Intravenous thrombolysis</topic><topic>Ischemia</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Patients</topic><topic>Risk assessment</topic><topic>Stroke</topic><topic>Systematic review</topic><topic>Thrombolysis</topic><topic>Tirofiban</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Qianqian</creatorcontrib><creatorcontrib>Lu, Xianfu</creatorcontrib><creatorcontrib>Yang, Hong</creatorcontrib><creatorcontrib>Deng, Shan</creatorcontrib><creatorcontrib>Zhang, Jian</creatorcontrib><creatorcontrib>Chen, Shijian</creatorcontrib><creatorcontrib>Shi, Shengliang</creatorcontrib><creatorcontrib>Xun, Weiquan</creatorcontrib><creatorcontrib>Peng, Rihong</creatorcontrib><creatorcontrib>Lin, Baoquan</creatorcontrib><creatorcontrib>Li, Tao</creatorcontrib><creatorcontrib>Pan, Liya</creatorcontrib><creatorcontrib>Weng, Baohui</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology Journals</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Qianqian</au><au>Lu, Xianfu</au><au>Yang, Hong</au><au>Deng, Shan</au><au>Zhang, Jian</au><au>Chen, Shijian</au><au>Shi, Shengliang</au><au>Xun, Weiquan</au><au>Peng, Rihong</au><au>Lin, Baoquan</au><au>Li, Tao</au><au>Pan, Liya</au><au>Weng, Baohui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><date>2022-11</date><risdate>2022</risdate><volume>222</volume><spage>107449</spage><pages>107449-</pages><artnum>107449</artnum><issn>0303-8467</issn><eissn>1872-6968</eissn><abstract>In the present systematic review and meta-analysis, we sought to compare the efficacy and safety of tirofiban administered in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT) with or without mechanical thrombectomy (MT).
We searched PubMed, Web of Science, Embase and the Cochrane Library for randomized clinical trials and observational studies published between 2001 and 2021 that provided outcomes of AIS patients who underwent IVT alone or IVT bridging with or without tirofiban. The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–2 at 90 days. The secondary outcomes included the rates of (1) an excellent outcome defined as a mRS score of 0 or 1 at 90 days, (2) any type of intracranial hemorrhage (ICH), (3) symptomatic intracranial hemorrhage (sICH), (4) mortality, and (5) successful recanalization.
We included 722 patients with IVT bridging therapy in 3 trials; there were 171 patients in the tirofiban group and 551 patients in the nontirofiban group. We included 846 patients with IVT alone in 7 studies; there were 471 patients in the tirofiban group and 375 patients in the nontirofiban group. The patients treated with tirofiban had a reduced risk of mortality compared to the patients treated without tirofiban during IVT bridging (OR, 0.46; 95 % CI, 0.24–0.89; p = 0.02), but no significant differences were found in safety outcomes on sICH, ICH, recanalization or efficacy outcomes on modified Rankin scale 0–2 (p > 0.05). Pooled results showed that tirofiban combined with IVT alone did not increase the risks of sICH, ICH or mortality but was significantly associated with excellent (OR, 2.68; 95 % CI, 1.58–4.55; P = 0.0003) and favorable (OR, 2.36; 95 % CI, 1.58–3.52; p < 0.0001) functional outcomes at 90 days.
In AIS patients who underwent IVT or bridging therapy, early administration of tirofiban may be effective and safe, but further studies are needed to confirm the efficacy.
•To evaluate the safety and efficacy of tirofiban therapy in patients with AIS after IVT.•Tirofiban could improve the 3-month functional outcome of AIS patients.•Tirofiban after IVT did not increase the risk of sICH or ICH.•Tirofiban reduced the mortality of AIS patients when administered in IVT bridging therapy.</abstract><cop>Assen</cop><pub>Elsevier B.V</pub><doi>10.1016/j.clineuro.2022.107449</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0303-8467 |
ispartof | Clinical neurology and neurosurgery, 2022-11, Vol.222, p.107449, Article 107449 |
issn | 0303-8467 1872-6968 |
language | eng |
recordid | cdi_proquest_journals_2727397425 |
source | Elsevier |
subjects | Acute ischemic stroke Bridging therapy Citation management software Clinical trials Collaboration FDA approval Glycoproteins Hemorrhage Intravenous administration Intravenous thrombolysis Ischemia Meta-analysis Mortality Observational studies Patients Risk assessment Stroke Systematic review Thrombolysis Tirofiban |
title | Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy: Systematic review and meta-analysis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A09%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20tirofiban%20administration%20for%20patients%20with%20acute%20ischemic%20stroke%20treated%20with%20intravenous%20thrombolysis%20or%20bridging%20therapy:%20Systematic%20review%20and%20meta-analysis&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Liu,%20Qianqian&rft.date=2022-11&rft.volume=222&rft.spage=107449&rft.pages=107449-&rft.artnum=107449&rft.issn=0303-8467&rft.eissn=1872-6968&rft_id=info:doi/10.1016/j.clineuro.2022.107449&rft_dat=%3Cproquest_cross%3E2727397425%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-cd8c11b35cbabdf5b6ab19ce9c01b6a93a9616757100b35cec00458a2296bbf83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2727397425&rft_id=info:pmid/&rfr_iscdi=true |